Dr. Postow on Entrectinib in Melanoma

Michael A. Postow, MD
Published: Wednesday, Nov 15, 2017



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Following more comprehensive molecular profiling, there are different genetic fusion events or other types of activating mutations, states Postow. There is a new fusion that has been discovered around NTRK that affects patients with advanced melanoma.

There are some promising strategies being used to target NTRK fusion, such as entrectinib, Postow explains.
 


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Following more comprehensive molecular profiling, there are different genetic fusion events or other types of activating mutations, states Postow. There is a new fusion that has been discovered around NTRK that affects patients with advanced melanoma.

There are some promising strategies being used to target NTRK fusion, such as entrectinib, Postow explains.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x